TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33202093
Drug: YH12852 0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 0.3, 0.5, 1, 2, or 3 mg
Study: 33202093
Drug: YH12852 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 0.05 or 0.1 mg
Study: 33202093
Drug: YH12852 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 (all doses)
Study: 32359393
Drug: Qing Qiao
Normalized name: qing feng teng stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing Qiao Capsule
Study: 32359393
Drug: Caefaclor capsule
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caefaclor capsule (Control)
Study: 35661157
Drug: Neoadjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant ipilimumab 1 mg kg−1 and nivolumab 3 mg kg−1 for 6 weeks
Study: 35661157
Drug: TLND and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLND and adjuvant systemic therapy ± synchronous radiotherapy for patients with pathologic non-response (pNR)
Study: 33957336
Drug: Tiagabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (15 mg)
Study: 35001439
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) administration as a complement to standard treatment
Study: 35001439
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus non-convalescent plasma (control)
Study: 35904750
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (acetyl-salicylic acid plus a P2Y12 inhibitor)
Study: 35904750
Drug: Antiplatelet monotherapy
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet monotherapy (a P2Y12 inhibitor) plus low dose anticoagulant (rivaroxaban, 15mg oral dose)
Study: 32927668
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g per day of cocoa-rich chocolate (99%) for 6 months
Study: 36217289
Drug: Rabbit Anti-Thymocyte
Normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit Anti-Thymocyte Globulin (rATG) 5 mg/kg from days -5 to -2
Study: 33333285
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg, qd, from the first day postoperatively, for 2 weeks)
Study: 33333285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine analgesic regimens including injection of cocktail mixture intraoperatively, oral celecoxib and tramadol postoperatively)
Study: 33977506
Drug: Losartan 12.5
Normalized name: losartan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 12.5 mg orally every 12 h for 10 days plus standard of care (SOC)
Study: 32114516
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) and optimal medical therapy (OMT)
Study: 35312632
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg)
Study: 34283529
Drug: Neurouridin dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurouridin dietary supplement
Study: 32105112
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure (COPE)
Study: 34981420
Drug: IV norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV norepinephrine + oral midodrine 10 mg thrice a day
Study: 35316858
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy along with conscious sedation (Group A)
Study: 32098012
Drug: Propofol-based anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based anesthesia (intravenous anesthetic)
Study: 32512710
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of porcine placenta extract once daily for 4 weeks
Study: 616172503
Drug: NT-proBNP guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP guided therapy (group 1)
Study: 616172503
Drug: Standard heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heart failure therapy (group 2)
Study: 35861908
Drug: Class IIa
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class IIa medical device containing lactic acid, azelaic acid/polyglyceryl‐3 copolymer, azelamidopropyl dimethyl amine, and bifida ferment lysate, used twice daily for 2 months
Study: 34265576
Drug: Plantago major
Normalized name: Plantago major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago major seed (3600 mg/day)
Study: 33334195
Drug: Xylitol tablets
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol tablets with red propolis (XPT)
Study: 33334195
Drug: Xylitol tablets
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol tablets without red propolis (XT)
Study: 32546239
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment for 6 months
Study: 33772845
Drug: Pramlintide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide infusion
Study: 36479786
Drug: Early glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early glargine group (subcutaneous insulin glargine 0.3 units/kg within the first 3 hours of DKA diagnosis, in addition to standard IV insulin infusion)
Study: 36479786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard IV insulin treatment only)
Study: 32930090
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to an equivalent dose of quetiapine, aripiprazole, or olanzapine with brief psychoeducation and support.
Study: 33533074
Drug: Melasolv™ applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melasolv™ applied twice a day for 12 weeks
Study: 33533074
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice a day for 12 weeks
Study: 34477291
Drug: Home Treatment
Normalized name: Home-brew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Treatment (HT)
Study: 34699618
Drug: Nitazoxanide 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 1,500 mg orally twice-daily with food for 7 days
Study: 33771722
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 80 μg via Breezhaler® (low-dose ICS)
Study: 33771722
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 320 μg via Breezhaler® (high-dose ICS)
Study: 33771722
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate via Breezhaler® (50-400 μg)
Study: 33771722
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate via Twisthaler® (200 μg and 800 μg)
Study: 32429874
Drug: Less invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less invasive surfactant administration via nasal route (LISA-n)
Study: 36253574
Drug: Adjunctive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive virtual classroom training (VCT) with the FRS curriculum
Study: 36253574
Drug: Adjunctive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive virtual classroom training (VCT) after initial training with FRS curriculum
Study: 34587568
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) intervention
Study: 36235546
Drug: Enhanced parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced parenteral nutrition (higher glucose infusion rate and intralipids)
Study: 36235546
Drug: Enhanced parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced parenteral nutrition
Study: 32801649
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of amitriptyline hydrochloride (25 mg)
Study: 32801649
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of amitriptyline hydrochloride (25 mg)
Study: 34887325
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone
Study: 36053364
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g kg-1 body mass NaHCO3 in chilled orange squash
Study: 36053364
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g kg-1 body mass NaHCO3 in capsules
Study: 36053364
Drug: Placebo (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.03 g kg-1 body mass sodium chloride)
Study: 33830626
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 units/mL (degludec)
Study: 33280425
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL (glargine U100)
Study: 33825140
Drug: Vitamin-K1 [10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-K1 [10 mg/day]
Study: 33825140
Drug: Colchicine [0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine [0.5 mg/day]
Study: 34916643
Drug: Four-implant overdentures
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-implant overdentures in the maxilla
Study: 33202169
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg, 2 tablets three times a day for 14 days)
Study: 32200486
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus metformin
Study: 38838170
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant zoster vaccine (RZV)
Study: 34315695
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (2 g sachet daily)
Study: 34315695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no probiotic supplements)
Study: 37700375
Drug: Metformin intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin intervention
Study: 36004716
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension
Study: 36402160
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules
Study: 35560315
Drug: Fortified BEP
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified BEP supplements and IFA
Study: 37126332
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection
Study: 34938352
Drug: Sulfadiazine Silver
Normalized name: Sulfadiazine silver
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadiazine Silver Cream (SSC)
Study: 32869324
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from warfarin to a direct oral anticoagulant after hospitalization
Study: 32873251
Drug: 5Gy x
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5Gy x 5 fractions of short-course radiation therapy (SCRT) followed by 6 cycles of mFOLFOX-6 plus avelumab
Study: 34518988
Drug: Tislelizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (monoclonal antibody)
Study: 32993766
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) in addition to standard treatment (dressings, debridement, antibiotics, load relief)
Study: 32993766
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (dressings, debridement, antibiotics, load relief)
Study: 33279389
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori treatment
Study: 34231473
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 2)
Study: 34231473
Drug: 0.5 L
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 L of polyethylene glycol (PEG)/ascorbic acid booster solution after the capsule reached the small intestine (group 3)
Study: 34231473
Drug: Clear liquid
Normalized name: Ensure Clear Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquid diet and fasting-based bowel preparation (group 1)
Study: 36041790
Drug: HIF-prolyl-hydroxyl domain
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIF-prolyl-hydroxyl domain (PHD) inhibitors (roxadustat, vadadustat, daprodustat)
Study: 33274388
Drug: Early headgear
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early headgear activator treatment
Study: 35662833
Drug: Masupirdine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masupirdine 50 mg
Study: 35662833
Drug: Masupirdine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masupirdine 100 mg
Study: 32436830
Drug: Intravenous reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous reperfusion therapy (IVT)
Study: 32436830
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase combined with mechanical thrombectomy (IAT)
Study: 32436830
Drug: No cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cerebral reperfusion therapy (NCRT)
Study: 35614019
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (group 3)
Study: 34744750
Drug: SHR-1222 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1222 (50 mg, n = 4; 100, 200, 300, or 400 mg, n = 9)
Study: 32619223
Drug: ZnP (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnP (1.0 g/[hd · d] additional Zn)
Study: 32619223
Drug: CON (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (0.0 g/[hd · d] of additional Zn)
Study: 34940066
Drug: 3-monthly cardiac
Normalized name: LEONURUS CARDIACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly cardiac monitoring
Study: 34940066
Drug: 4-monthly cardiac
Normalized name: LEONURUS CARDIACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-monthly cardiac monitoring
Study: 35051971
Drug: Specialized outpatient
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized outpatient physical therapy (PT) program
Study: 34448282
Drug: Probiotics supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics supplemented quadruple therapy
Study: 34448282
Drug: Probiotics monotherapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics monotherapy
Study: 32398065
Drug: Antibiotic stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic stewardship programme implemented in intervention arm, including training for family physicians, improved management and peer-review of antibiotic prescribing, improved electronic medical records and smartphone app facilitation, patient education via family physicians, leaflets, and videos.
Study: 35796224
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 5% gel
Study: 35796224
Drug: Topical methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical methotrexate 1% gel
Study: 34474706
Drug: Subcutaneous allergy
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergy immunotherapy for short ragweed, timothy grass, Dermatophagoides pteronyssinus, and cat and dog dander.
Study: 34474706
Drug: Sublingual allergy
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergy immunotherapy (approved tablets).
Study: 34474706
Drug: General analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: General analysis of dosing practices by U.S. allergists.
Study: 33028566
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin
Study: 34178863
Drug: Chlorella vulgaris
Normalized name: CHLORELLA VULGARIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella vulgaris (CV) 900 mg/day
Study: 32036492
Drug: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
Study: 32036492
Drug: 5-fluorouracil/l-leucovorin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/l-leucovorin plus paclitaxel (FLTAX)
Study: 32036492
Drug: 5-fluorouracil/l-leucovin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/l-leucovin plus paclitaxel (FLTAX)
Study: 32086187
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of caffeine
Study: 32667240
Drug: Collective Narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collective Narrative Therapy Groups (CNTG)
Study: 33662176
Drug: Bi-monthly household
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-monthly household visits
Study: 32521976
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS)
Study: 32865027
Drug: Telehealth visits
Normalized name: Guaifenesin 100 mg in 5 mL ORAL LIQUID [SelectHealth Tussin DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth visits (weekly to biweekly)
Study: 32865027
Drug: Telephone calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone calls (monthly)
Study: 32631710
Drug: Sienna XP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sienna XP (1 mL)
Study: 32631710
Drug: Sienna XP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sienna XP (1.5 mL)
Study: 32631710
Drug: Sienna XP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sienna XP (2 mL)
Study: 32911242
Drug: Multi-component pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-component pre-operative preparation program (including informative booklet, preoperative tour, educational DVD, therapeutic play intervention)
Study: 32911242
Drug: Informative booklet
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informative booklet as routine information preparation
Study: 32898357
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 120 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 118.2 ± 10.0 HU.
Study: 32898357
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 90 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 141.0 ± 18.2 HU.
Study: 32898357
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 100 kV tube voltage, CM dose 0.417 g I/kg; O: Mean attenuation 117.6 ± 13.9 HU.
Study: 32898357
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: 90 kV tube voltage, CM dose 0.365 g I/kg; O: Mean attenuation 117.3 ± 21.6 HU.
Study: 33399241
Drug: Palbociclib added
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib added to endocrine therapy
Study: 34527924
Drug: Paraffin bath
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin bath therapy (20 min, one session per day, for two weeks)
Study: 34527924
Drug: Fluidotherapy (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluidotherapy (same duration and frequency as paraffin bath therapy)
Study: 32959458
Drug: CGRP (calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP (calcitonin gene-related peptide) intravenous infusion at 1.5μg/min over 20 minutes
Study: 32959458
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline) intravenous infusion over 20 minutes
Study: 35899020
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine with 5 μg dexmedetomidine (group BD)
Study: 35899020
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine with 10 mg meperidine (group BM)
Study: 33183558
Drug: Inorganic NO3-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic NO3- tablets (314 mM NO3-)
Study: 33183558
Drug: Placebo (NO3-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NO3- free tablets)
Study: 35926074
Drug: Curated social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curated social web application (interactive website) for COVID-19 vaccine confidence
Study: 36151976
Drug: Comfort‐in™ injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfort‐in™ injection system (CIS)
Study: 35909329
Drug: EV 2
Normalized name: Padcev 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV 2 mg + DNG 2-3 mg (n=20)
Study: 35909329
Drug: EE 0.03
Normalized name: EE 0.03MG/LEVONORG 0.15MG TAB,28
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 0.03 mg + DNG 2 mg (n=20)
Study: 35909329
Drug: DNG 2
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNG 2 mg (n=19)
Study: 32142501
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg once daily for 6 weeks
Study: 32142501
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg once daily for 6 months